×
GCLAM therapy shows promise for relapsed/refractory AML
https://www.mdedge.com/oncologypractice/article/160195/aml/gclam-therapy-shows-promise-relapsed/refractory-aml

Jun 2nd, 2008 - The phase 1/2 trial evaluated combined G-CSF, cladribine, high-dose cytarabine, and mitoxantrone in adults with relapsed/refractory AML.

Rapid test could solve Africa’s sickle cell screening problem
https://www.mdedge.com/hematologynews/article/190657/anemia/rapid-test-could-solve-africas-sickle-cell-screening-problem

Dec 7th, 2018 - The simple blood test costs about $2 and has an accuracy of 99%.

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML
https://www.cancertherapyadvisor.com/chronic-myeloid-leukemia/eutos-long-term-survival-score-outperforms-sokal-tki-treated-cml/article/819747/

Dec 7th, 2018 - The EUTOS long-term survival score (ELTS) better discriminates patients for risk stratification than the standard Sokal score, according to findings from an analysis of data from 904 patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) who had enrolled in 6 multicenter studies.

VTE Clinical Practice Guidelines
https://content.jwplatform.com/players/IN0W1T7P-Y8T7ZZf0.html

Dec 7th, 2018 - Six new Clinical Practice Guidelines on Venous Thromboembolism have just been announced.

Choosing Wisely Champions Initiative
https://content.jwplatform.com/players/jc7zyb6N-Y8T7ZZf0.html

Dec 7th, 2018 - Each year, ASH’s Choosing Wisely Champions Initiative recognizes three practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures.

Plenary Scientific Session
https://content.jwplatform.com/players/uuJmGHb6-Y8T7ZZf0.html

Dec 7th, 2018 - The plenary scientific session is a highlight of the annual meeting, where attendees hear presentations of the 6 highest caliber scientific abstracts.

Late Breaking Abstracts & Best of ASH
https://content.jwplatform.com/players/PZ7jwRI8-Y8T7ZZf0.html

Dec 7th, 2018 - A preview of the Late Breaking Abstracts and The Best of ASH.

Global Programs & Capacity Building Showcase
https://content.jwplatform.com/players/qo6WKBvL-Y8T7ZZf0.html

Dec 7th, 2018 - The society continues to grow its international influence and help improve hematologic care around the globe.

Look Ahead to 2019
https://content.jwplatform.com/players/yJp2IcQE-Y8T7ZZf0.html

Dec 7th, 2018 - A look ahead to 2019, with ASH President-Elect, Dr. Roy Silverstein

Dynamic Scientific Panels & Presentations
https://content.jwplatform.com/players/PwoNW63L-Y8T7ZZf0.html

Dec 7th, 2018 - A look at some of the dynamic scientific panels and presentations including the new frontier of glycobiology and new insights into neonatal hematology

Highlights from Scientific Spotlight Sessions
https://content.jwplatform.com/players/Pu7DTVEk-Y8T7ZZf0.html

Dec 7th, 2018 - Scientific spotlight sessions at the ASH annual meeting provided an in-depth review of specific scientific topics.

Clinical Practice Guidelines for SCD
https://content.jwplatform.com/players/WKvxizqD-Y8T7ZZf0.html

Dec 7th, 2018 - ASH is developing new clinical practice guidelines on the management of acute and chronic complications of sickle cell disease

Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL
https://www.cancertherapyadvisor.com/ash-2018/leukemia-cll-ibrutinib-rituximab-reportedly-superior-younger-patients-risk/article/819194/

Dec 6th, 2018 - The combination of ibrutinib and rituximab provided superior progression-free survival and, after follow-up, superior overall survival, compared with the current standard of care, chemoimmunotherapy (CIT) fludarabine, cyclophosphamide, and rituximab (FCR), in treatment-naive patients younger than 70 years with chronic lymphocytic leukemia (CLL), according to research presented at a late-breakin...

Another Rituximab Biosimilar Passes Lymphoma Test
https://www.medpagetoday.com/meetingcoverage/ashhematology/76747

Dec 6th, 2018 - A rituximab biosimilar demonstrated noninferiority to European (EU)-licensed rituximab (MabThera) in a randomized trial involving patients with low-tumor burden follicular lymphoma

Daratumumab Plus Len/Dex: New Standard of Care in Myeloma?
https://www.medscape.com/viewarticle/906121

Dec 6th, 2018 - In the MAIA study, adding the monoclonal antibody daratumumab (Darzalex, Janssen) to standard therapy significantly extended progression-free survival (PFS) in patients newly diagnosed with multiple myeloma who were ineligible for stem cell transplant.

The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma
http://www.cancernetwork.com/ash-lymphoma/long-term-outlook-mogamulizumab-previously-treated-cutaneous-t-cell-lymphoma

Dec 6th, 2018 - The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.

Rivaroxaban may reduce VTE risk in cancer patients
https://www.mdedge.com/hematologynews/article/190551/thrombosis/rivaroxaban-may-reduce-vte-risk-cancer-patients

Dec 6th, 2018 - The CASSINI trial evaluates VTE prophylaxis in ambulatory patients receiving systemic therapy.

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
https://www.cancertherapyadvisor.com/multiple-myeloma/multiple-myeloma-daratumumab-combo-new-standard-care-transplant-risk/article/819214/

Dec 6th, 2018 - Adding daratumumab to standard treatment with lenalidomide and dexamethasone (DRd) reduced the risk of progression or death by 44% among patients with transplant-ineligible newly-diagnosed multiple myeloma, according to an interim analysis of data from the randomized, open-label, multicenter phase 3 MAIA clinical trial

In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remission
https://www.mdedge.com/hematologynews/article/190344/aml/idh-mutated-aml-first-line-idh-inhibitors-plus-chemo-may-boost

Dec 5th, 2018 - Minimal residual disease and mutational clearance were seen in a significant proportion of patients.

Rivaroxaban Reduced VTE and VTE-Related Death in Patients With Cancer: Results of the CASSINI Study
https://www.cancertherapyadvisor.com/ash-2018/rivaroxaban-vte-lower-risk-cassini-results-treatment/article/819105/

Dec 5th, 2018 - Results from the randomized, phase 3b superiority study, CASSINI, on rivaroxaban thromboprophylaxis in high-risk patients who received systemic therapy, were revealed during a late-breaking abstract session at the 2018 American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.1 The investigators determined that rivaroxaban, which is not yet approved in this set...